Derbise Anne, Hanada Yuri, Khalifé Manal, Carniel Elisabeth, Demeure Christian E
Unité de recherche Yersinia, Institut Pasteur, Paris, France.
PLoS Negl Trop Dis. 2015 Oct 16;9(10):e0004162. doi: 10.1371/journal.pntd.0004162. eCollection 2015.
No efficient vaccine against plague is currently available. We previously showed that a genetically attenuated Yersinia pseudotuberculosis producing the Yersinia pestis F1 antigen was an efficient live oral vaccine against pneumonic plague. This candidate vaccine however failed to confer full protection against bubonic plague and did not produce F1 stably.
METHODOLOGY/PRINCIPAL FINDINGS: The caf operon encoding F1 was inserted into the chromosome of a genetically attenuated Y. pseudotuberculosis, yielding the VTnF1 strain, which stably produced the F1 capsule. Given orally to mice, VTnF1 persisted two weeks in the mouse gut and induced a high humoral response targeting both F1 and other Y. pestis antigens. The strong cellular response elicited was directed mostly against targets other than F1, but also against F1. It involved cells with a Th1-Th17 effector profile, producing IFNγ, IL-17, and IL-10. A single oral dose (108 CFU) of VTnF1 conferred 100% protection against pneumonic plague using a high-dose challenge (3,300 LD50) caused by the fully virulent Y. pestis CO92. Moreover, vaccination protected 100% of mice from bubonic plague caused by a challenge with 100 LD50 Y. pestis and 93% against a high-dose infection (10,000 LD50). Protection involved fast-acting mechanisms controlling Y. pestis spread out of the injection site, and the protection provided was long-lasting, with 93% and 50% of mice surviving bubonic and pneumonic plague respectively, six months after vaccination. Vaccinated mice also survived bubonic and pneumonic plague caused by a high-dose of non-encapsulated (F1-) Y. pestis.
VTnF1 is an easy-to-produce, genetically stable plague vaccine candidate, providing a highly efficient and long-lasting protection against both bubonic and pneumonic plague caused by wild type or un-encapsulated (F1-negative) Y. pestis. To our knowledge, VTnF1 is the only plague vaccine ever reported that could provide high and durable protection against the two forms of plague after a single oral administration.
目前尚无有效的鼠疫疫苗。我们之前表明,一种产生鼠疫耶尔森菌F1抗原的基因减毒假结核耶尔森菌是一种有效的预防肺鼠疫的口服活疫苗。然而,这种候选疫苗未能对腺鼠疫提供全面保护,且不能稳定产生F1。
方法/主要发现:将编码F1的caf操纵子插入基因减毒假结核耶尔森菌的染色体中,产生VTnF1菌株,该菌株能稳定产生F1荚膜。给小鼠口服后,VTnF1在小鼠肠道中持续存在两周,并诱导针对F1和其他鼠疫耶尔森菌抗原的强烈体液反应。引发的强烈细胞反应主要针对F1以外的靶点,但也针对F1。它涉及具有Th1-Th17效应特征的细胞,产生IFNγ、IL-17和IL-10。单剂量口服(108 CFU)VTnF1使用由完全有毒的鼠疫耶尔森菌CO92引起的高剂量攻击(3300 LD50),对肺鼠疫提供了100%的保护。此外,疫苗接种保护100%的小鼠免受100 LD50鼠疫耶尔森菌攻击引起的腺鼠疫,以及93%免受高剂量感染(10000 LD50)。保护涉及控制鼠疫耶尔森菌从注射部位扩散的快速作用机制,并且提供的保护是持久的,接种疫苗后六个月,分别有93%和50%的小鼠在腺鼠疫和肺鼠疫中存活。接种疫苗的小鼠也在由高剂量非荚膜(F1-)鼠疫耶尔森菌引起的腺鼠疫和肺鼠疫中存活。
VTnF1是一种易于生产、基因稳定的鼠疫疫苗候选物,对由野生型或非荚膜(F1阴性)鼠疫耶尔森菌引起的腺鼠疫和肺鼠疫提供高效且持久的保护。据我们所知,VTnF1是有史以来报道的唯一一种单次口服给药后能对两种鼠疫形式提供高度持久保护的鼠疫疫苗。